TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer

Summary

The purpose of the study is to learn from the real world practice of prescribing targeted therapies to patients with advanced cancer whose tumor harbors a genomic variant known to be a drug target or to predict sensitivity to a drug.

NOTE: Due to character limits, the arms section does NOT include all TAPUR Study relevant biomarkers. For additional information, contact [email protected], or if a patient, your nearest participating TAPUR site (see participating centers).

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Results in publication or poster presentation format are posted as they become available for individual cohorts at www.tapur.org/news. The results may be accessed at any time. All results will be made available on clinicaltrials.gov at the end of the study. Indexing of available results on PubMed is in progress.

\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*\*

Conditions

• Lymphoma, Non-Hodgkin
• Multiple Myeloma
• Advanced Solid Tumors

Interventions

DRUG

Palbociclib

drug

DRUG

Sunitinib

drug

DRUG

Temsirolimus

drug

DRUG

Trastuzumab and Pertuzumab

drug

DRUG

Vemurafenib and Cobimetinib

drug

DRUG

Regorafenib

drug

DRUG

Olaparib

drug

DRUG

Nivolumab and Ipilimumab

drug

DRUG

Abemaciclib

drug

DRUG

Talazoparib

drug

DRUG

Atezolizumab and Talazoparib

drug

DRUG

Tucatinib plus Trastuzumab Subcutaneous (SC)

drug

DRUG

Futibatinib

drug

DRUG

Dabrafenib plus Trametinib

Drug

DRUG

Fam-Trastuzumab Deruxtecan-Nxki (TDxD)

Drug

Sponsors & Collaborators

• American Society of Clinical Oncology

  lead OTHER

• AstraZeneca

  collaborator INDUSTRY

• Bayer

  collaborator INDUSTRY

• Bristol-Myers Squibb

  collaborator INDUSTRY

• Eli Lilly and Company

  collaborator INDUSTRY

• Genentech, Inc.

  collaborator INDUSTRY

• Pfizer

  collaborator INDUSTRY

• Taiho Oncology, Inc.

  collaborator INDUSTRY

• Novartis

  collaborator INDUSTRY

• Merck Institute for Therapeutic Research

  collaborator UNKNOWN

• Boehringer Ingelheim

  collaborator INDUSTRY

• Seattle Genetics (now a wholly owned subsidiary of Pfizer)

  collaborator UNKNOWN

Study Design

Allocation

NON_RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Model

SINGLE_GROUP

Eligibility

Min Age

12 Years

Sex

ALL

Healthy Volunteers

No

Timeline & Regulatory

Start

2016-03-14

Primary Completion

2027-12-31

Completion

2028-12-31

Countries

• United States

Study Locations